FDA advisers weigh Moderna’s mRNA flu shot after 40,000-person study showed 27% relative efficacy

A U.S. FDA expert advisory committee is reviewing Moderna’s mRNA-based influenza vaccine candidate, mFlusiva. In a 40,000-person study of adults 50 and older, the shot showed about 27% relative efficacy versus another routinely used flu vaccine, and the FDA’s preliminary review reported no safety concerns. Moderna is seeking full approval for use in people ages 50 to 64 and authorization for those 65 and older while additional testing continues. The development is a clear regulatory and commercialization milestone for Moderna’s stock, with no direct link to commodities, indices, or macro assets.